Relatlimab

Relatlimab (BMS-986016) is a monoclonal antibody targeting human anti-LAG-3, generated by immunization of transgenic mice with human immunoglobulin carrying recombinant LAG-3 protein.Relatlimab has a blocking effect, blocking the interaction of LAG-3/MHC II (IC50: 0.67 nM) and LAG-3/FGL1 (IC50: 0.019 nM) . Relatlimab is often used with Nivoluma to treat advanced melanoma.